Otsuka Holdings Co., Ltd.: Parkinson Disease trials

The registry lists 12 Parkinson Disease studies with Otsuka Holdings Co., Ltd. as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 7Phase 3 5Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease PsychosisCompletedNCT02969369Phase 2Results posted
• Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease PatientsCompletedNCT01767129Phase 2Results posted
• A Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsCompletedNCT01634243Phase 2Results posted
• A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01631825Phase 3Results posted
• A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01631812Phase 2Results posted
• A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease PatientsCompletedNCT01628965Phase 2/3Results posted
• A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01628926Phase 3Results posted
• A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01628848Phase 2Results posted
• A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease PatientsCompletedNCT00537485Phase 2/3Results posted
• PRISM Registry: Pseudobulbar Affect Registry SeriesCompletedNCT01366027
• Aripiprazole in Patients With Psychosis Associated With Parkinson's DiseaseCompletedNCT00095810Phase 4
• Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)CompletedNCT00056524Phase 3